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ABSTRACT 
Objective: This study aims to identify the methodology of incompatibility assay. This review is intended to inform further research into the 
management of these issues in a clinical setting in Indonesia.  
Methods: A search was conducted of incompatibility studies through International Pharmaceutical Abstract (IPA) using the keywords 
‘compatibility’ OR ’incompatibility” AND ‘intravenous”, “parenteral” OR “infusion”. 
Results: There are only two authors use in vivo setting and higher number of authors use in vitro setting. Among those who bring in vitro assays 
most of them use static approach between two drug combination.  
Conclusion: A standardized procedure is meaningful for general judgement for incompatibility. However, particularly in critical care, setting up an 
evaluation procedure that mimics as closely as possible real practice within the clinical area should be undertaken to validate practice.  
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INTRODUCTION 
Intravenous (IV) delivery is extensively used for many reasons; it 
has rapid onset, high bioavailability, rapid clearance once stopped, 
and therefore is suitable for dose titration and maintenance of effect. 
In particular, patients in intensive care, with multiple and complex 
conditions receive numerous intravenous medications. Frequently 
the number of IV medication is more than number of venous access 
lumens for these patients. Consequently, co- administration of more 
than one medication in the same container, or same line, is 
inevitable. Evidence shows adding of additional lumens increases 
opportunities for infection, and multi lumen CVC’s increase the risk of 
catheter related blood stream infection [1]. A larger number of 
medications will increase the incompatibility risk geometrically [2]. 
However, this complex situation is poorly understood by health staff [3]. 
Previous studies found incompatibility problems in up to 18.6% of 
critical care patients and 18.7% of continuously infused medications 
[4]. This percentage differs from that found in general wards at only 
3% [5]. The pivotal issue in compatibility problems is how to assess 
the evidence. This arises from up to 25% conflicting data in 
reference sources to determine compatible (C), incompatible (I), or 
compatible in the specific circumstances (C/I) [4].  
Foinard also identified highly variable results in the frequency of 
incompatibility ranging from 0.2 to 25% of drug combinations used, 
resulting from differences of methodology of the compatibility 
studies [6]. This difference is induced by the variation in specific 
brand, concentration, flow rate, infusion device, and also 
circumstance [3]. Kanji also found a minimum of 10% difference 
with the practical setting in components assayed, conditions, and 
duration studied [4]. This creates difficulties for health professionals 
in making decisions related to incompatibility. 
Incompatibility leads to technical and clinical complications such as 
occlusion, and reduced potency or even negation of the therapeutic 
effect of medications. It can also lead to local and systemic 
inflammatory reactions. The benefit of incompatibility studies 
therefore avoids these risks for the patient, and also possible lethal 
effects as in previous reports of the FDA and others [3, 4]. 
In analysing the problem, it was identified that incompatibility still 
happens as a result of conflicting incompatibility information. One of 
the causes of conflicting data relates to methodology. Underlying this 
problem is a question of how the examination of incompatibility was 
approached and how the method relates to practice in critical care. 
Studies on incompatibility began many years ago, but development 
of methods for the study of incompatibility has not progressed as 
quickly as medication discovery. This review aims to examine 
incompatibility assays and how they can be related to practical 
therapy.  
MATERIALS AND METHODS 
A search was conducted of incompatibility studies through 
International Pharmaceutical Abstract (IPA). From broad reports 406 
publications were identified from 1970-2013 using the keywords 
‘compatibility’ OR ’incompatibility AND ‘intravenous”, “parenteral”, 
OR “infusion”. The studies were examined for methodology that they 
used.  
RESULTS 
Incompatibility assays were identified using in vitro and in vivo 
methods. Most of the incompatibility assays identified used an in 
vitro approach.  
In Vivo Approach 
Only two studies were identified using this approach. Reyes and 
Jaimovich, both used porcine model [7,8]. Jaimovich measured 
compatibility in the mixture of diluted product, and also in the blood, 
from administration through a peripheral site using a double-lumen 
catheter [7, 8]. Meanwhile, Reyes used a triple lumen central venous 
catheter to understand the influence of infusion length toward the 
incompatibility. Ten domestic porcine weighing 10-20 kg were 
administered Total Parenteral Nutrition (TPN) through the distal 
port of the device and phenytoin as bolus or as an infusion. The 
experimental lumen was inserted into femoral vein. Samples were 
collected from other ports at 1, 5, 10, and 15 minutes. Particle was 
measured by phase-contrast light microscopy, and wright stain 
smears.  
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In Vitro Approach 
There are many studies in drug compatibility using in vitro methods. 
There are two major sub-sets for this approach; static and dynamic 
methods; 
a. Static method.  
Many investigators have used this approach to measure 
incompatibility in IV admixtures. Some of medications are mixed in 
the same container or syringes before administration into an 
infusion set. This method is commonly used for parenteral nutrition, 
and also for antibiotics with diluents [9]. In a practical setting, such 
mixtures are mostly prepared by pharmacists and delivered by a 
nurse at the bedside, so they require validated storage time before 
administration. During storage, an incompatibility reaction may 
occur amongst the components of the mixture. Prior admixing was 
associated with a higher risk of incompatibility compared to ‘y-site’ 
administration, where medications are added into separate tubes 
which come together at a common ‘y’ connection close to the patient. 
It is often believed by many health professionals that this method 
avoids physical and chemical incompatibility issues.  
In detailed methods, the in vitro approach uses a glass container or 
syringe to blend all of the components. A filter is commonly used for 
reducing particulate matter before mixing as this may ‘scratch a 
precipitate’ that otherwise might not occur. To ensure homogeneity, 
the mixture also is getting vortexes. All procedures were undertaken 
at room temperature and sterile conditions in a biological safety 
cabinet with range of 18-24o Celsius. Most observations were 
undertaken at time 0 and 24 hours. This is intended to reflect the 
probable maximum time of storage of this mixture before delivery to 
patients.  
b. Dynamic method 
The dynamic method is mostly used to describe the incremental step 
method. For incompatibility studies, this term is frequently related 
to assay methods for incompatibility at ‘y-site’ connections or in 
tubing where the components of IV medications may possibly come 
into contact with one another. This method was initiated by Allen in 
his 1977 study [3]. The study was designed to more closely simulate 
the actual conditions in hospital. It uses an infusion set that is filled 
with a large volume IV solution, to which is added primary additives 
(such as vitamin B, Potassium Chloride, or heparin) into the carrier 
solution and also secondary additives (medications) from syringes 
through syringe-ports. Contact between the medications was 
predicted in y-site injections. Incompatibility was assessed from a 
sample from the needle tip in 0 and 4 hours.  
Allen reported that incompatibility will be expected at the y-site 
when the resultant mixture is in a 1:1 ratio. This finding becomes 
important for incompatibility assay. Most study that followed Allen’s 
procedure used the same ratio of 1:1 and an observation window of 
4 hours. This was also reinforced by Trissel and Martinezas the basis 
for a fixed method for incompatibility testing [11]. Trissel is a major 
author in this subject area. His paper is widely cited to identify y-site 
incompatibility using methodology described as ‘simulated y-site. 
Trissel used the term ‘simulated y-site’ to classify the incompatibility 
test for medication that is mixed in the same tubing or line. The 
difference of procedure compared to Allen is Trissel’s method does 
not use an infusion set. This method is therefore closer to the static 
method. Using same assumption as Allen, it utilises a vial or glass 
flask for mixing medications in a ratio 1:1. To minimize risk, drug 
concentration is maintained below the maximum concentration that 
can be used in the clinical situation [12]. In this method, medications 
are mixed in a clear glass tube and measured in 0 minutes, 30 
minutes, 60 minutes, and 4 hours. All manipulation takes place in a 
class 100 biological safety cabinet at room temperature in duplicate. 
Here it is important to note that many critical care areas will 
typically be warmer than normal room temperature (25oC). A 
modified method was conducted by Husson, et al. that used a 
continuous infusion via an infusion line and extracted samples at the 
end of tube for assessing incompatibility [13]. This approach takes 
place in a dynamic way. Husson assembled an infusion line as in 
practical setting. The evaluation was observed along the line and in 
the collection bag at the distal end of the line at 0, 30, 60, and 75 
minutes. This approach is more accurately termed dynamic rather 
than Trissel’s approach. It used an infusion line flowing at a specific 
rate.  
Servais and Tulkens also developed a similar method to Husson by 
mimicking as closely as possible the projected routine used in a 
Belgian hospital [14]. They used an infusion line to measure 
incompatibility between ceftazidime and other drugs that were 
commonly delivered in the same line. This study is closer to 
modelling the true clinical situation. Not only modelling the clinical 
area set-up with a running infusion line, but also for the brand name 
of drugs, diluents, concentration, flow rate, and circumstances 
following the routine procedure in their hospital.  
Collins and Lutz developed a method of incompatibility study 
utilizing not only in a single lumen but also in multi-lumen catheter 
[15]. Previously, there has been a presumption that when another 
medication is co-administered separated in a different lumen of a 
multi-lumen device, it will not be in contact with any other 
medication and incompatibility will be avoided. However, this study 
concluded that adjacent lumens particularly in a double lumen 
device; gives a possibility for rapid incompatibility reactions for 
example between phenytoin and parenteral nutrition. Precipitation 
was identified in the double lumen system, but it did not appear in 
the triple lumen system.  
DISCUSSION 
Each of the identified approaches to the identification of 
incompatibility has limitations in terms of answering problems in a 
clinical setting. In vivo studies are superior in terms of the complex 
considerations including physiological considerations. It tries to 
consider intravascular pressure, respiratory cycles, neurovascular, 
and also thermoregulatory factors that may influence vascular size 
and flow. Vasculature and blood flow may affect the infusion stream, 
although to what extent requires further investigation. These 
changes can influence particle formation through flow turbulence. 
The major limitation is that it is expensive, requires an animal or 
human subject and the associated ethical issues. Consequently the 
majority of incompatibility assays are conducted in the in vitro 
setting. This is reflected in the incompatibility definition. The US 
National Coordinating Committee on Large Volume Parenteral (NCC-
LVP) defines incompatibility as a phenomenon which occurs when 
one drug is mixed with others to produce, by physicochemical 
means, a product unsuitable for administration to the patient [2]. 
Bergman also stated that is only in vitro incompatibilities pertaining 
to LVP systems that are considered, while potential in vivo effects 
are termed by drug-drug interactions.  
An in vitro study is simpler and less expensive. The main reason to 
use this approach is that many incompatibility reactions happen in 
an in vitro setting. The medications in the mixture react in the 
container or in the line before entering to human body. It assumes 
that there is no correlation between physiological change and in 
vitro reaction outside the body. However, Jaimovich demonstrated 
that direct clinical applicability is limited for in vitro testing. It 
doesn’t reflect the changes in the body that may affect vessels and 
flow in the vessel [8]. He also found that precipitation is influenced 
by turbulence in blood flow with changing vascular structure. 
Unfortunately this assumption has not yet been confirmed with 
other studies. In vitro modelling is therefore limited but the risk of 
incompatibility can be assessed in an advanced methodology 
bringing some modelling of the in vivo situation. Currently, the 
commonly referenced studies for incompatibility use an in vitro 
approach with simulated ‘y-site’ as described by Trissel. This type of 
study is useful for the judgement of incompatibility within a fixed 
procedure. Practitioners can interpret the data more readily, but 
applicability is limited to the conditions prevailing within those 
studies. This approach tends to use a static rather than a dynamic 
model that is not illustrating the real conditions. Currently, most of 
databases used to inform critical care use different study conditions 
to the projected routine use in critical care. In addition, the 
European Pharmacopeia recommends assaying incompatibility in 
triplicate rather than the duplicate as used by Trissel [12,17].  
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Critical care patients are especially vulnerable to incompatibility 
issues due to the number of medications, the use of multi-lumen 
devices, changing flow rate of infusion including changeover of 
medication, interruption and resumption of drug flow, and also the 
specific circumstances of temperature or humidity and light. At 
present, critical care patients require multi-lumen catheters for their 
multiple medications. They typically receive around 10 different 
medications. Currently, there is assumption that multi-lumen 
divided medications can avoid incompatibility. However, 
incompatibility studies using multi-lumen devices are 
underreported [15].  
Typically more than 60% of medication for critical care patients is 
continuous or intermittent intravenous [16]. However this is a 
dynamic situation with specific rate for each individual, not a static 
standardised approach. Few of the studies identified that flow rate 
impacts on incompatibility. Yet a simple physicochemical theory 
shows that flow rate impacts upon the number and quantity of 
medications that may come into contact within the infusion system. 
For a medication that has an incompatibility reaction which is dose-
dependent, flow rate may influence the reaction. The study from 
Foinard acknowledged that physical incompatibility is influenced by 
drug concentration, flow rate, and infusion device [6]. Foinard 
confirmed that flow rate influenced incompatibility, and that 
dynamic models that also consider flow-rate have been 
underutilised to date. It appears clear that there is a need for more 
controlled in vitro studies mimicking common situations in clinical 
practice in order to address directly this issue in hospital practice.  
Regarding the use of published information, practitioners need to be 
aware of study methodology issues. It must also be recognised in 
this age of proliferation of generic products that existing studies 
relate to a specific brand name, concentration, duration, and also 
temperature. Trissel highlighted the need to interpret carefully 
before applying the data in his data base [16]. For example, 
incompatibility that occurred in 4 hours cannot be concluded that 
the drug is safe before 4 hours. The observation may be not done 
before 4 hours. More than 60% of studies observed the 
incompatibility during up to 4 hours. In the most of study, the 
incompatibility was measured previously at 1 hour then at 4 hours. 
The reaction may have happened in the interval. Increasing 
temperature also raises the reaction rate. Many reports only 
performed a partial evaluation; physical or chemical incompatibility. 
They did not investigate incompatibility comprehensively. There 
remains a need for more studies, modelling closely the actual 
conditions of use. These need to be stated in the publications along 
with all the equipment used within the model infusion system. This 
can be collated into a central resource. Practitioners also need to 
understand that there should be no substitution or extrapolation of 
these studies without validation.  
CONCLUSION 
In vitro assay is recommended for incompatibility study. A 
standardized procedure following the methods of Allen and Trissel 
are meaningful for general judgement for incompatibility. However, 
particularly in critical care, setting up an evaluation procedure that 
mimics as closely as possible real practice within the clinical area 
should be undertaken to validate practice.  
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